These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
51. Para-aortic plus pelvic lymphadenectomy in locally advanced cervical cancer: A single institutional experience. Mezquita G; Muruzabal JC; Perez B; Aguirre S; Villafranca E; Jurado M Eur J Obstet Gynecol Reprod Biol; 2019 May; 236():79-83. PubMed ID: 30889424 [TBL] [Abstract][Full Text] [Related]
52. Residual pelvic lymph node involvement after concomitant chemoradiation for locally advanced cervical cancer. Houvenaeghel G; Lelievre L; Rigouard AL; Buttarelli M; Jacquemier J; Viens P; Gonzague-Casabianca L Gynecol Oncol; 2006 Jul; 102(1):74-9. PubMed ID: 16406062 [TBL] [Abstract][Full Text] [Related]
53. [The indication and surgery scope for laparoscopic extraperitoneal lymphadenectomy in locally advanced cervical cancer]. Zhong ML; Liang MR; Jiang W; Wang YN; Zeng Y; Zeng SY Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):303-308. PubMed ID: 31014057 [No Abstract] [Full Text] [Related]
54. Is there a benefit of pretreatment laparoscopic transperitoneal surgical staging in patients with advanced cervical cancer? Marnitz S; Köhler C; Roth C; Füller J; Hinkelbein W; Schneider A Gynecol Oncol; 2005 Dec; 99(3):536-44. PubMed ID: 16126259 [TBL] [Abstract][Full Text] [Related]
55. Implications of extraperitoneal paraaortic lymphadenectomy to the left renal vein in locally advanced cervical cancer. A Spanish multicenter study. Díaz-Feijoo B; Franco S; Torné A; Benito V; Hernández A; Lago V; Rovira R; Acosta Ú; Agustí N; Gil-Moreno A; Gynecol Oncol; 2020 Aug; 158(2):287-293. PubMed ID: 32467055 [TBL] [Abstract][Full Text] [Related]
56. Patients with locally advanced cervical cancer should not undergo routine pretreatment surgical staging. Mota F; De Oliveira C Eur J Gynaecol Oncol; 2006; 27(2):109-14. PubMed ID: 16620049 [TBL] [Abstract][Full Text] [Related]
57. Selection of patients with advanced-stage cervical cancer for para-aortic lymphadenectomy in the era of PET/CT. Margulies AL; Peres A; Barranger E; Perreti I; Brouland JF; Toubet E; Sarda-Mantel LE; Thoury A; Chis C; Walker F; Luton D; Delpech Y; Koskas M Anticancer Res; 2013 Jan; 33(1):283-6. PubMed ID: 23267158 [TBL] [Abstract][Full Text] [Related]
59. Prognostic Impact of Pretreatment Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography SUVmax in Patients With Locally Advanced Cervical Cancer. Cima S; Perrone AM; Castellucci P; Macchia G; Buwenge M; Cammelli S; Cilla S; Ferioli M; Ferrandina G; Galuppi A; Salizzoni E; Rubino D; Fanti S; De Iaco P; Morganti AG Int J Gynecol Cancer; 2018 Mar; 28(3):575-580. PubMed ID: 29372911 [TBL] [Abstract][Full Text] [Related]
60. A prospective randomized trial to study the impact of pretreatment FDG-PET for cervical cancer patients with MRI-detected positive pelvic but negative para-aortic lymphadenopathy. Tsai CS; Lai CH; Chang TC; Yen TC; Ng KK; Hsueh S; Lee SP; Hong JH Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):477-84. PubMed ID: 19464824 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]